CTOs on the Move

Octant Bio

www.octant.bio

 
Octant is a well-backed team of experienced scientists and entrepreneurs exploring new frontiers of biology. We are applying next-generation DNA sequencing, gene synthesis, and gene editing to revolutionize drug discovery in a quest for safer, more effective, and cheaper drugs.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Octant Bio raised $30M on 05/20/2020

Similar Companies

Thrive Health Plans

Thrive Health Plans is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kyowa Pharmaceutical

Kyowa Pharmaceutical is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AccessDx Laboratory

Learn why 2,000+ healthcare organizations and employers depend on our experts to improve patient outcomes with advanced diagnostics.

Carisma Therapeutics

Carisma Therapeutics Inc. is a clinical stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. The first applications of the platform, developed in collaboration with the University of Pennsylvania, are autologous chimeric antigen receptor (CAR)-macrophages for the treatment of solid tumors. Carisma Therapeutics is headquartered in Philadelphia, PA.

Ambys

Ambys Medicines is a biotechnology company focused on discovering and developing regenerative and restorative therapies for people with advanced liver disease. Founded by world-renowned experts in liver disease and regenerative medicine, Ambys is pioneering the application of novel modalities including cell and gene therapy, and gain-of-function drug therapy, to meet the urgent need for treatments that have the potential to restore liver function and prevent the progression to liver failure across multiple liver diseases that are untreatable or poorly treated today. Ambys was launched in 2018 by Third Rock Ventures and Takeda Pharmaceuticals with $140M in starting capital and is headquartered in South San Francisco, Calif.